Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GLUL | P15104 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | ARG2 | P78540 | 3/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747426 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| SCHEMBL21747440 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| SCHEMBL21747424 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| SCHEMBL1192036 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| Ap-7 SCHEMBL12648647 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| Ap-7 SCHEMBL9848541 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747427 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747430 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747425 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747439 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 846 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | OrphAl Therapeutics Inc. (US) | 2026-03-31 | — | — | US | claimed |
| WO-2025065271-A1 | METHODS AND DEVICES FOR TREATING DEPRESSION | Liangzhu Laboratory (CN) | 2025-04-03 | — | — | WO | claimed |
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | claimed |
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | claimed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | claimed |
| CN-118684620-A | Betel nut alkaloid and preparation method and application thereof | 暨南大学 | 2024-09-24 | — | — | CN | claimed |
| CN-117929747-A | Biomarker for severity of ischemic cerebral apoplexy and application thereof | 浙江中医药大学 | 2024-04-26 | — | — | CN | claimed |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | OrphAl Therapeutics Inc. (US) | 2024-04-16 | — | — | US | claimed |
| US-20240024332-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ACADIA WOODS PARTNERS, LLC | 2024-01-25 | — | — | US | claimed |
| EP-4291565-A1 | SYNTHETIC CINCHONA ALKALOIDS AGAINST CANCER | Ares Pharmaceuticals, LLC (US) | 2023-12-20 | — | — | EP | claimed |
| EP-1954665-A1 | INHIBITORS OF KYNURENINE AMINOTRANSFERASE AND USES THEREFOR | The University of Maryland, Baltimore (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1903028-A1 | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects | Tschollar,, Werner (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2007064784-A1 | INHIBITORS OF KYNURENINE AMINOTRANSFERASE AND USES THEREFOR | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2007-06-07 | — | — | WO | claimed |
| EP-0797442-B1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 2003-05-21 | — | — | EP | claimed |
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | claimed |
| EP-0533832-A4 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | US COMMERCE (US) | 1993-04-28 | — | — | EP | claimed |
| EP-0533832-A1 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1993-03-31 | — | — | EP | claimed |
| WO-1991019493-A1 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-12-26 | — | — | WO | claimed |
| EP-0432994-A2 | Excitatory amino acid antagonists as anti-emetic drugs | Olney, John William (US) | 1991-06-19 | — | — | EP | claimed |
| WO-1988007851-A1 | LIPOSOME ENTRAPPED N-METHYL-D-ASPARTATE RECEPTOR BLOCKERS | INNOVATIVE THERAPEUTICS CORPORATION (US) | 1988-10-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | ZAP70, PIK3R4, PIKFYVE | BHMT 1790/4885POLB 4455/4885KMT2A 1620/4885 |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | GRIK4, GRIN3A, GRIN2A | BHMT 918/4885POLB 3371/4885KMT2A 748/4885 |
| US-20240024332-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | GRIN3A, GRIN2A, GRIK4 | BHMT 515/4885POLB 2870/4885KMT2A 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.